165 related articles for article (PubMed ID: 37549770)
21. Design, synthesis & biological evaluation of ferulic acid-based small molecule inhibitors against tumor-associated carbonic anhydrase IX.
Aneja B; Queen A; Khan P; Shamsi F; Hussain A; Hasan P; Rizvi MMA; Daniliuc CG; Alajmi MF; Mohsin M; Hassan MI; Abid M
Bioorg Med Chem; 2020 May; 28(9):115424. PubMed ID: 32209296
[TBL] [Abstract][Full Text] [Related]
22. NIR phosphorescent cyclometalated platinum (II) complexes with CAIX targeted and nuclear penetration as potent anticancer theragnostic agents.
Yang J; Chen DL; Wang PC; Yang B; Gao CZ
Eur J Med Chem; 2022 Dec; 243():114702. PubMed ID: 36084533
[TBL] [Abstract][Full Text] [Related]
23. Carbonic Anhydrase IX Suppression Shifts Partial Response to Checkpoint Inhibitors into Complete Tumor Eradication: Model-Based Investigation.
Grajek J; Poleszczuk J
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373220
[TBL] [Abstract][Full Text] [Related]
24. Inclusion of a 5-fluorouracil moiety in nitrogenous bases derivatives as human carbonic anhydrase IX and XII inhibitors produced a targeted action against MDA-MB-231 and T47D breast cancer cells.
Petreni A; Bonardi A; Lomelino C; Osman SM; ALOthman ZA; Eldehna WM; El-Haggar R; McKenna R; Nocentini A; Supuran CT
Eur J Med Chem; 2020 Mar; 190():112112. PubMed ID: 32044580
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.
Ward C; Meehan J; Mullen P; Supuran C; Dixon JM; Thomas JS; Winum JY; Lambin P; Dubois L; Pavathaneni NK; Jarman EJ; Renshaw L; Um IH; Kay C; Harrison DJ; Kunkler IH; Langdon SP
Oncotarget; 2015 Sep; 6(28):24856-70. PubMed ID: 26259239
[TBL] [Abstract][Full Text] [Related]
26. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
27. A Carbonic Anhydrase IX (CAIX)-Anchored Rhenium(I) Photosensitizer Evokes Pyroptosis for Enhanced Anti-Tumor Immunity.
Su X; Wang WJ; Cao Q; Zhang H; Liu B; Ling Y; Zhou X; Mao ZW
Angew Chem Int Ed Engl; 2022 Feb; 61(8):e202115800. PubMed ID: 34842317
[TBL] [Abstract][Full Text] [Related]
28. Picomolar fluorescent probes for compound affinity determination to carbonic anhydrase IX expressed in live cancer cells.
Matulienė J; Žvinys G; Petrauskas V; Kvietkauskaitė A; Zakšauskas A; Shubin K; Zubrienė A; Baranauskienė L; Kačenauskaitė L; Kopanchuk S; Veiksina S; Paketurytė-Latvė V; Smirnovienė J; Juozapaitienė V; Mickevičiūtė A; Michailovienė V; Jachno J; Stravinskienė D; Sližienė A; Petrošiūtė A; Becker HM; Kazokaitė-Adomaitienė J; Yaromina A; Čapkauskaitė E; Rinken A; Dudutienė V; Dubois LJ; Matulis D
Sci Rep; 2022 Oct; 12(1):17644. PubMed ID: 36271018
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?
Möhring C; Timotheou A; Mańczak A; Sadeghlar F; Zhou T; Mahn R; Bartels A; Monin M; Toma M; Feldmann G; Brossart P; Köksal M; Sarria GR; Giordano FA; Lingohr P; Jafari A; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
J Cancer Res Clin Oncol; 2023 May; 149(5):1849-1862. PubMed ID: 35763109
[TBL] [Abstract][Full Text] [Related]
30. Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX.
Murri-Plesko MT; Hulikova A; Oosterwijk E; Scott AM; Zortea A; Harris AL; Ritter G; Old L; Bauer S; Swietach P; Renner C
Eur J Pharmacol; 2011 Apr; 657(1-3):173-83. PubMed ID: 21315712
[TBL] [Abstract][Full Text] [Related]
31. Activation of carbonic anhydrase IX by alternatively spliced tissue factor under late-stage tumor conditions.
Ramchandani D; Unruh D; Lewis CS; Bogdanov VY; Weber GF
Lab Invest; 2016 Dec; 96(12):1234-1245. PubMed ID: 27721473
[TBL] [Abstract][Full Text] [Related]
32. Expression and activity of carbonic anhydrase IX is associated with metabolic dysfunction in MDA-MB-231 breast cancer cells.
Li Y; Wang H; Oosterwijk E; Tu C; Shiverick KT; Silverman DN; Frost SC
Cancer Invest; 2009 Jul; 27(6):613-23. PubMed ID: 19367501
[TBL] [Abstract][Full Text] [Related]
33. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion.
Robertson N; Potter C; Harris AL
Cancer Res; 2004 Sep; 64(17):6160-5. PubMed ID: 15342400
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
35. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs.
Dubois L; Peeters SG; van Kuijk SJ; Yaromina A; Lieuwes NG; Saraya R; Biemans R; Rami M; Parvathaneni NK; Vullo D; Vooijs M; Supuran CT; Winum JY; Lambin P
Radiother Oncol; 2013 Sep; 108(3):523-8. PubMed ID: 23849171
[TBL] [Abstract][Full Text] [Related]
36. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
Pernot S; Mitry E; Samalin E; Dahan L; Dalban C; Ychou M; Seitz JF; Turki H; Mazard T; Zaanan A; Lepère C; Vaillant JN; Landi B; Rougier P; Taieb J
Gastric Cancer; 2014 Apr; 17(2):341-7. PubMed ID: 23739764
[TBL] [Abstract][Full Text] [Related]
37. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
Lorenzen S; Pauligk C; Homann N; Schmalenberg H; Jäger E; Al-Batran SE
Br J Cancer; 2013 Feb; 108(3):519-26. PubMed ID: 23322206
[TBL] [Abstract][Full Text] [Related]
39. Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer.
Galletti G; Zhang C; Gjyrezi A; Cleveland K; Zhang J; Powell S; Thakkar PV; Betel D; Shah MA; Giannakakou P
Clin Cancer Res; 2020 Jul; 26(14):3771-3783. PubMed ID: 32321717
[TBL] [Abstract][Full Text] [Related]
40. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E
Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
